NCT00860457 - Lenalidomide Following Fludarabine/Rituximab (FR) in Untreated Chronic Lymphocytic Leukemia (CLL) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

February 29, 2008

Primary Completion Date

March 31, 2011

Study Completion Date

February 29, 2012

Conditions

Chronic Lymphocytic Leukemia

Interventions

DRUG

Rituximab

375 mg/m2 IV infusion Day 1 of each 28-day cycle for maximum of 6 cycles

DRUG

Fludarabine

25 mg/m2 IV Days 1-5 of each 28-day cycle for maximum of 6 cycles

DRUG

Lenalidomide

5-10 mg PO daily on Days 1-21 of each 28-day cycle for a maximum of 6 cycles

Trial Locations (1)

Lombardi Cancer Center at Georgetown University Medical Center, Washington D.C.